Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2014-09-30 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Cytos Biotechnology Ltd reports the financial results of the First Half Year 2014
Earnings Release Classification · 100% confidence The document explicitly states it reports the "financial results of the First Half Year 2014" and provides a consolidated financial summary (Revenue, Operating loss, Net loss) for the six-month period ended June 30, 2014. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is an announcement, it contains the core financial highlights and summary tables, making it more specific than a general RPA or RNS. The length (5131 chars) is substantial enough to contain key results rather than just a pointer to a report. H1 2014
2014-09-30 English
Cytos Biotechnology Ltd to wind down Key Operational Activities
Regulatory Filings Classification · 95% confidence The document is titled 'News Details' and is released as an 'Ad-hoc' announcement on May 5, 2014. It discusses significant strategic company decisions, including winding down operational activities, reducing liabilities, concluding employee dismissals, and reducing the size of the board of directors. This type of material, which announces major, non-routine corporate events outside of standard periodic reporting (like 10-K or IR), is typically classified as a general regulatory announcement or a significant corporate event disclosure. Since it doesn't fit the specific definitions for M&A (TAR), Capital Change (CAP/SHA), Director Dealing (DIRS), or Dividend (DIV), and it is not a transcript (CT) or a formal report (10-K, IR), the most appropriate general category for an unscheduled, material corporate update that is not otherwise specified is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2014-05-05 English
Cytos Biotechnology Ltd (SIX:CYTN) today published the topline results of the global Phase 2b clinical trial with CYT003.
Earnings Release Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 14, 2014, detailing the 'topline results' of a Phase 2b clinical trial for a drug candidate (CYT003). It explicitly mentions the failure to meet primary endpoints, the subsequent decision to wind down operations and liquidate, and the impact on convertible loans and employee dismissals. This content is a primary announcement of significant, time-sensitive business and financial developments, typical of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on the immediate release of key performance results (clinical trial outcome) that trigger major corporate actions (liquidation), it aligns best with the 'Earnings Release' (ER) category, which covers the initial announcement of periodical/key results, even though this is a clinical result rather than quarterly financials. Given the context of a Swiss company (SIX listing) releasing ad-hoc news, it is a mandatory disclosure of material information. It is not a full report (10-K, IR), a presentation (IP), or a management discussion (MDA). It is the initial release of the critical outcome. Q1 2014
2014-04-14 English
Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approved all proposals and resolutions
AGM Information Classification · 99% confidence The document explicitly states in the headline and body that it concerns the 'Annual Shareholders’ Meeting of Cytos Biotechnology Ltd' and that shareholders 'approved all proposals and resolutions'. The document is tagged with the keyword 'AGM/EGM'. This directly corresponds to the definition of AGM Information (Code: AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2014-04-03 English
Cytos Biotechnology Ltd announces amendment of convertible loan notes agreement
Regulatory Filings Classification · 95% confidence The document is a press release dated March 31, 2014, titled "Cytos Biotechnology Ltd announces amendment of convertible loan notes agreement." It discusses a material change in financing terms (conversion of loan notes into shares upon clinical trial success) and is explicitly labeled as an "Ad-hoc" announcement pursuant to regulatory rules ("Art. 53 KR"). This type of announcement, detailing significant corporate actions outside of standard periodic reports (like 10-K or IR), fits best under the general category for regulatory/material news that isn't specifically covered by other codes like DIV, SHA, or CAP (which usually relates to raising new capital, not restructuring existing debt terms in this manner). Since it is a material, non-standard announcement distributed via a news service (EQS), and it doesn't fit the specific definitions for ER, IR, or CT, the most appropriate general classification for significant, non-periodic regulatory news is RNS (Regulatory Filings/General Regulatory Announcements).
2014-03-31 English
Cytos Biotechnology Ltd invites to the Annual Shareholders' Meeting in April 2014
AGM Information Classification · 99% confidence The document explicitly announces the date, time, and location for the 'Annual Shareholders' Meeting 2014' and provides a link to the invitation, which includes the agenda. The key phrase is 'Cytos invites to the Annual Shareholders' Meeting 2014'. This directly corresponds to the definition of AGM Information (AGM-R). Although it is an announcement, the content is specifically about the AGM event itself, making AGM-R a better fit than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2014-03-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.